Search

Your search keyword '"Bonmarin, I"' showing total 141 results
Start Over Author "Bonmarin, I"
141 results on '"Bonmarin, I"'

4. Clinical characteristics and outcome of respiratory syncytial virus infection among adults hospitalized with influenza-like illness in France

Author

Seddik, K., Lesieur, Z., Bonmarin, I., Loulergue, P., Bodilis, H., Servera-Miyalou, M., Sadler, I., Momcilovic, S., Kanaan, R., Coolent, N., Tan Boun, K., Blanche, P., Charpentier, J., Daviaud, F., Mongardon, N., Bretagnol, A., Claessens, Y.E., Rozenberg, F., Yazdanpanah, Y., Burdet, C., Harent, S., Lachatre, M., Rioux, C., Bleibtreu, A., Casalino, E., Choquet, C., Leleu, A., Belghalem, K., Colosi, L., Ranaivoson, M., Verry, V., Pereira, L., Dupeyrat, E., Bernard, J., Emeyrat, N., Chavance, P., Debit, A., Aubier, M., Pradere, P., Justet, A., Mal, H., Brugiere, O., Papo, T., Goulenok, T., Boisseau, M., Jouenne, R., Alexandra, J.F., Raynaud-Simon, A., Lilamand, M., Cloppet-Fontaine, A., Becheur, K., Pelletier, A.L., Fidouh, N., Ralaimazava, P., Beaumale, F., Costa, Y., Munier, E., Betend, F., Amour, S., Loeffert, S., Francourt, K., Merle, C., Letois, F., Géraud, P., Driss, V., Noslier, S., Ray, M., Sebbane, M., Konaté, A., Bourdin, A., Klouche, K., Léglise, M.S., Couve-Deacon, E., Fruit, D., Fenerol, C., Vallejo, C., Jouneau, S., Lainé, F., Thébault, E., Fillatre, P., Le Pape, C., Beuzit, L., Chau, F., Carrat, F., Goderel, I., Loubet, P., Lenzi, N., Valette, M., Foulongne, V., Krivine, A., Houhou, N., Lagathu, G., Rogez, S., Alain, S., Duval, X., Galtier, F., Postil, D., Tattevin, P., Vanhems, P., Lina, B., and Launay, O.

Published
2017
Full Text
View/download PDF

5. Additional file 1 of Initial risk perception and feeling of preparedness of primary care physicians regarding the COVID-19 pandemic in Belgium, France and Spain in February 2020

Author

Guerrisi, C, Thomas, B, Ordax Diez, A, Van Cauteren, D, Lozano Alonso, J E, Moreels, S, Falchi, A, Vega Alonso, T, Bonmarin, I, Raude, J, Vilcu, A M, Hanslik, T, Debin, M, Rossignol, L, Colizza, V, Souty, C, and Blanchon, T

Subjects
genetic structures, sense organs, behavioral disciplines and activities, psychological phenomena and processes
Abstract

Additional file 1. Physicians��� questionnaire on early perception of the COVID-19 pandemic.

Published
2022
Full Text
View/download PDF

9. Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection

Author

Venkatesan, S, Myles, PR, Bolton, KJ, Muthuri, SG, Al Khuwaitir, T, Anovadiya, AP, Azziz-Baumgartner, E, Bajjou, T, Bassetti, M, Beovic, B, Bertisch, B, Bonmarin, I, Booy, R, Borja-Aburto, VH, Burgmann, H, Cao, B, Carratala, J, Chinbayar, T, Cilloniz, C, Denholm, JT, Dominguez, SR, Duarte, PAD, Dubnov-Raz, G, Fanella, S, Gao, Z, Gerardin, P, Giannella, M, Gubbels, S, Herberg, J, Higuera Iglesias, AL, Hoeger, PH, Hu, XY, Islam, QT, Jimenez, MF, Keijzers, G, Khalili, H, Kusznierz, G, Kuzman, I, Langenegger, E, Lankarani, KB, Leo, Y-S, Libster, RP, Linko, R, Madanat, F, Maltezos, E, Mamun, A, Manabe, T, Metan, G, Mickiene, A, Mikic, D, Mohn, KG, Oliva, ME, Ozkan, M, Parekh, D, Paul, M, Rath, BA, Refaey, S, Rodriguez, AH, Sertogullarindan, B, Skret-Magierlo, J, Somer, A, Talarek, E, Tang, JW, To, K, Dat, T, Uyeki, TM, Vaudry, W, Vidmar, T, Zarogoulidis, P, Nguyen-Van-Tam, JS, Venkatesan, S, Myles, PR, Bolton, KJ, Muthuri, SG, Al Khuwaitir, T, Anovadiya, AP, Azziz-Baumgartner, E, Bajjou, T, Bassetti, M, Beovic, B, Bertisch, B, Bonmarin, I, Booy, R, Borja-Aburto, VH, Burgmann, H, Cao, B, Carratala, J, Chinbayar, T, Cilloniz, C, Denholm, JT, Dominguez, SR, Duarte, PAD, Dubnov-Raz, G, Fanella, S, Gao, Z, Gerardin, P, Giannella, M, Gubbels, S, Herberg, J, Higuera Iglesias, AL, Hoeger, PH, Hu, XY, Islam, QT, Jimenez, MF, Keijzers, G, Khalili, H, Kusznierz, G, Kuzman, I, Langenegger, E, Lankarani, KB, Leo, Y-S, Libster, RP, Linko, R, Madanat, F, Maltezos, E, Mamun, A, Manabe, T, Metan, G, Mickiene, A, Mikic, D, Mohn, KG, Oliva, ME, Ozkan, M, Parekh, D, Paul, M, Rath, BA, Refaey, S, Rodriguez, AH, Sertogullarindan, B, Skret-Magierlo, J, Somer, A, Talarek, E, Tang, JW, To, K, Dat, T, Uyeki, TM, Vaudry, W, Vidmar, T, Zarogoulidis, P, and Nguyen-Van-Tam, JS

Abstract

BACKGROUND: The effect of neuraminidase inhibitor (NAI) treatment on length of stay (LoS) in patients hospitalized with influenza is unclear. METHODS: We conducted a one-stage individual participant data (IPD) meta-analysis exploring the association between NAI treatment and LoS in patients hospitalized with 2009 influenza A(H1N1) virus (A[H1N1]pdm09) infection. Using mixed-effects negative binomial regression and adjusting for the propensity to receive NAI, antibiotic, and corticosteroid treatment, we calculated incidence rate ratios (IRRs) and 95% confidence intervals (CIs). Patients with a LoS of <1 day and those who died while hospitalized were excluded. RESULTS: We analyzed data on 18 309 patients from 70 clinical centers. After adjustment, NAI treatment initiated at hospitalization was associated with a 19% reduction in the LoS among patients with clinically suspected or laboratory-confirmed influenza A(H1N1)pdm09 infection (IRR, 0.81; 95% CI, .78-.85), compared with later or no initiation of NAI treatment. Similar statistically significant associations were seen in all clinical subgroups. NAI treatment (at any time), compared with no NAI treatment, and NAI treatment initiated <2 days after symptom onset, compared with later or no initiation of NAI treatment, showed mixed patterns of association with the LoS. CONCLUSIONS: When patients hospitalized with influenza are treated with NAIs, treatment initiated on admission, regardless of time since symptom onset, is associated with a reduced LoS, compared with later or no initiation of treatment.

Published
2020

15. Moderate influenza vaccine effectiveness against hospitalisation with A(H3N2) and A(H1N1) influenza in 2013–14: Results from the InNHOVE network

Author

Rondy, M., Castilla, J., Launay, O., Costanzo, S., Ezpeleta, C., Galtier, F., de Gaetano Donati, K., Moren, A., Beristain, X., Chamorro, J., Gabari, M., Artajo, P., Lameiro, F., Barrado, L., Ortega, M., Torres, M., Garcia Irure, J. J., Irisarri, F., Garcia Cenoz, M., Guevara, M., Casado, I., Diaz, J., Martinez-Baz, I., Lenzi, N., Lesieur, Z., Bonmarin, I., Merle, C., Foulongne, V., Letois, F., Driss, V., Geraud, P., Bourdin, A., Landreau, L., Konate, A., Corne, P., Sebbane, M., Klouche, K., Leglise, M. -S., Loulergue, P., Kanaan, R., Dumas, F., Krivine, A., Moncilovic, S., Ali, N., Duval, X., Costa, Y., Ait Naman, R., Yazdapanah, Y., Caseris, M., Dournon, N., Papo, T., Dossier, A., Becheur, H., Pelletier, A. -L., Mal, M., Marceau, A., Aubier, M., Bories, R., Casalino, E., Choquet, C., Houhou, N., Vanhems, P., Regis, C., Jouneau, S., Laine, F., Tattevin, P., Beuzit, L., Thebault, E., Fey, S., Lagathu et Sophie Cha, G., Postil, D., Alcolea, S., Rogez, S., Valette, M., Lina, B., Cauda, R., Taccari, F., Santangelo, R., Perlasca, F., Fichera, G., Dara, M., Iacoviello, L., Olivieri, M., CIC - Biotherapie - AP-HP (cochin - Pasteur), Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Saint-Eloi, CIC Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-CHU Saint-Eloi-Institut National de la Santé et de la Recherche Médicale (INSERM), Biocommunication en Cardio-Métabolique (BC2M), Université de Montpellier (UM), Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Saint Eloi (CHRU Montpellier), and Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
Male, [SDV]Life Sciences [q-bio], Logistic regression, medicine.disease_cause, Influenza A Virus, H1N1 Subtype, 0302 clinical medicine, Outcome Assessment, Health Care, Influenza A virus, Immunology and Allergy, Medicine, 030212 general & internal medicine, hospital, Young adult, media_common, Aged, 80 and over, Influenza vaccine, Vaccination, virus diseases, Middle Aged, Research Papers, 3. Good health, Hospitalization, case control studies, Italy, Influenza Vaccines, Female, France, Seasons, Adult, medicine.medical_specialty, Adolescent, 030231 tropical medicine, Immunology, Young Adult, 03 medical and health sciences, Internal medicine, Influenza, Human, A h1n1 influenza, Humans, media_common.cataloged_instance, European Union, European union, Intensive care medicine, Aged, Pharmacology, business.industry, Influenza A Virus, H3N2 Subtype, Case-control study, Influenza, multicentre studies, Logistic Models, Spain, Case-Control Studies, business, Sentinel Surveillance
Abstract

International audience; We conducted a multicentre test negative case control study to estimate the 2013–14 influenza vaccine effectiveness (IVE) against hospitalised laboratory confirmed influenza in 12 hospitals in France, Italy and Spain. We included all ≥18 years hospitalised patients targeted by local influenza vaccination campaign reporting an influenza-like illness within 7 days before admission. We defined as cases patients RT-PCR positive for influenza and as controls those negative for all influenza virus. We used a logistic regression to calculate IVE adjusted for country, month of onset, chronic diseases and age. We included 104 A(H1N1)pdm09, 157 A(H3N2) cases and 585 controls. The adjusted IVE was 42.8% (95%CI: 6.3;65;0) against A(H1N1)pdm09. It was respectively 61.4% (95%CI: −1.9;85.4), 39.4% (95%CI: −32.2;72.2) and 19.7% (95%CI:-148.1;74.0) among patients aged 18–64, 65–79 and ≥80 years. The adjusted IVE against A(H3N2) was 38.1% (95%CI: 8.3;58.2) overall. It was respectively 7.8% (95%CI: −145.3;65.4), 25.6% (95%CI: −36.0;59.2) and 55.2% (95%CI: 15.4;76.3) among patients aged 18–64, 65–79 and ≥80 years. These results suggest a moderate and age varying effectiveness of the 2013–14 influenza vaccine to prevent hospitalised laboratory-confirmed influenza. While vaccination remains the most effective prevention measure, developing more immunogenic influenza vaccines is needed to prevent severe outcomes among target groups. © 2016 Taylor & Francis.

Published
2016

17. EpiNano fait peau neuv

Author

Renaudie, N., primary, Tassy, V., additional, Iwatsubo, Y., additional, Sobczak, B., additional, Tordjman, I., additional, Maladry, P., additional, Delabre, L., additional, Ducamp, S., additional, Empereur-Bissonnet, P., additional, Bonmarin, I., additional, and Chami, K., additional

Published
2018
Full Text
View/download PDF

18. The potential risks and impact of the start of the 2015-2016 influenza season in the WHO European Region: a rapid risk assessment

Author

Tjon‐Kon‐Fat, Raïssa, Meerhoff, Tamara, Nikisins, Sergejs, Pires, João, Pereyaslov, Dmitriy, Gross, Diane, Brown, Caroline, Drishti, A., Hasibra, I., Kota, M., Simaku, A., Sarkisian, S., Torosyan, L., El Belazi, G., Hain, C., Lachner, P., Muchl, R., Popow‐Kraupp, T., Redlberger‐Fritz, M., Strauss, R., Abdullayeva, N., Salimov, O., Gribkova, N., Shimanovich, V., Bossuyt, N., Hombrouck, A., Moreels, S., Thomas, I., an Casteren, ., Bastinac, D., Dedejic Ljubovic, A., Kojic, D., Kovacevic Suljkanovic, M., Kuzmanovic, M., Vukmir Rodic, N., Georgieva, T., Kojouharova, M., Korsun, N., Drazenovic, V., Erceg, M., Kurecic‐Filipovic, S., Simunovic, A., Visekruna, V.V., Bagatzouni, D., Elia, A., Koliou, M., Havlickova, M., Jirincova, H., Kyncl, J., Bragstad, K., Kolsen Fischer, T., Krause, K.L., Mazick, A., Trebbien, R., Dontsenko, I., Dotsenko, L., Pokras, L., Sadikova, O., Ikonen, N., Lyytikainen, O., Murtopuro, S., Ruutu, P., Behillil, S., Belchior, E., Blanchon, T., Bonmarin, I., Bruno, L., Cohen, J.M., Enouf, V., Levy, B.D., Mosnier, A., Turbelin, C., Valette, M., an der Werf, ., Chakhunashvili, G., Machablishvili, A., Zakhashvili, K., Andreas, G., Buda, S., Eckmanns, T., Krause, G., Poggensee, G., Schweiger, B., Kossivakis, A., Malisiovas, N., Mentis, A., Spala, G., Csohan, A., Jankovics, I., Kaszas, K., Molnar, Z., Rozsa, M., Gudnason, T., Löve, A., Sigmundsdottir, G., Coughlan, S., Domegan, L., Duffy, M., Igoe, D., O'Donnell, J., O'Flanagan, D., Waters, A., Kaufman, Z., Mandelboim, M., Bella, A., Donatelli, I., Pompa, M.G., Rizzo, C., Amandosova, D., Kuatbaeva, A., Nusupbaeva, G., Smagulova, M., Smagul, M., Sultanova, M., Otorbaeva, D., Saparova, G., Butirina, R., Nikiforova, R., Storozenko, J., Zamjatina, N., Griskevicius, A., Lipnickiene, V., Muralyte, S., Mossong, J., Opp, M., Barbara, C., Graziella, Z., Maistre, M.J., Melillo, T., Rakocevic, B., Vratnica, Z., Hooiveld, I., de Lange, M., Dijkstra, F., Donker, G., Meijer, A., Rimmelzwaan, G., Teirlinck, A., van der Hoek, W., Dudman, S., Hauge, S.H., Hungnes, O., Kilander, A., Tonnessen, R., Bednarska, K., Brydak, L., Wozniak‐Kosek, A., Zielinski, A., Guiomar, R., Nunes, B., Eder, V., Spinu, C., Alexandrescu, V., Lupulescu, E., Popovici, F., Burtseva, E., Komissarov, A., Smorodintseva, E., Sominina, A., Dimitrijevic, D., Filipovic, S., Staronova, E., Berginc, N., Prosenc, K., Socan, M., Ucakar, V., Grgic Vitek, M., Casas, I., de Lejarazu, R. Ortiz, Larrauri, A., Pozo, F., Vega, T., Ali, M., Brytting, M., Dahl, H., Englund, H., Tegnell, A., Wallensten, A., Wiman, A., Born, R., Cordey, S., Kamolov, M., Bosevska, G., Karadzovski, Z., Kuzmanovska, G., Mikik, V., Korukluoglu, G., Topal, S., Ashyrova, A., Ovliyakulova, G., Demchyshyna, I., Dykhanovska, T., Mironenko, A., Blatchford, O., Carman, W., Coyle, P., Gunson, R., Kearns, C., MacLean, A., Mcmenamin, J., Moore, C., Nugent, C., Pebody, R., Phin, N., Reynolds, A., Smyth, B., Watson, J., Zambon, M., Dzemileva, S., and Rakhimov, R.

Subjects
0301 basic medicine, Pulmonary and Respiratory Medicine, Epidemiology, Influenza season, Influenza A(H1N1)pdm09 virus, influenza A(H1N1)pdm09 virus, Seasonal influenza, 03 medical and health sciences, Environmental protection, Virology, Environmental health, Estado de Saúde, 2015–2016 Influenza season, Public Health, Environmental and Occupational Health, virus diseases, 1103 Clinical Sciences, European region, 030112 virology, Europe, 030104 developmental biology, Infectious Diseases, Geography, 1117 Public Health And Health Services, 2015-2016 Influenza season, Original Article, seasonal influenza, Determinantes da Saúde e da Doença, WHO European Region, Risk assessment
Abstract

WHO European Region Influenza Network: P.Conde, I. Costa, P. Crostovão, R. Guiomar, B. Nunes, P.Pechirra, A. Rodrigues (Portugal) BACKGROUND: Countries in the World Health Organization (WHO) European Region are reporting more severe influenza activity in the 2015-2016 season compared to previous seasons. OBJECTIVES: To conduct a rapid risk assessment to provide interim information on the severity of the current influenza season METHODS: Using the WHO manual for rapid risk assessment of acute public health events and surveillance data available from Flu News Europe, an assessment of the current influenza season from 28 September 2015 (week 40/2015) up to 31 January 2016 (week 04/2016) was made compared with the 4 previous seasons. RESULTS: The current influenza season started around week 51/2015 with higher influenza activity reported in eastern Europe compared to Western Europe. There is a strong predominance of influenza A(H1N1)pdm09 compared to previous seasons, but the virus is antigenically similar to the strain included in the seasonal influenza vaccine. Compared to the 2014/2015 season, there was a rapid increase in the number of severe cases in eastern European countries with the majority of such cases occurring among adults aged

Published
2016

19. Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an IPD meta-analysis

Author

Muthuri, SG, Venkatesan, S, Myles, PR, Leonardi-Bee, J, Lim, WS, Mamun, AA, Anovadiya, AP, Araújo, WN, Azziz-Baumgartner, E, Báez, C, Bantar, C, Barhoush, MM, Bassetti, M, Beovic, B, Bingisser, R, Bonmarin, I, Borja-Aburto, VH, Cao, B, Carratala, J, Cuezzo, MR, Denholm, JT, Dominguez, SR, Duarte, PA, Dubnov-Raz, G, Echavarria, M, Fanella, S, Fraser, J, Gao, Z, Gérardin, P, Giannella, M, Gubbels, S, Herberg, J, Iglesias, AL, Hoeger, PH, Hoffmann, M, Hu, X, Islam, QT, Jiménez, MF, Kandeel, A, Keijzers, G, Khalili, H, Khandaker, G, Knight, M, Kusznierz, G, Kuzman, I, Kwan, AM, Amine, IL, Langenegger, E, Lankarani, KB, Leo, YS, Linko, R, Liu, P, Madanat, F, Manabe, T, Mayo-Montero, E, McGeer, A, Memish, ZA, Metan, G, Mikić, D, Mohn, KG, Moradi, A, Nymadawa, P, Ozbay, B, Ozkan, M, Parekh, D, Paul, M, Poeppl, W, Polack, FP, Rath, BA, Rodríguez, AH, Siqueira, MM, Skręt-Magierło, J, Talarek, E, Tang, JW, Torres, A, Törün, SH, Tran, D, Uyeki, TM, Van Zwol, A, Vaudry, W, Velyvyte, D, Vidmar, T, Zarogoulidis, P, PRIDE Consortium Investigators, and Nguyen-Van-Tam, JS

Subjects
1117 Public Health And Health Services, hospitalisation, Virology, individual participant data meta-analyses, 1103 Clinical Sciences, Influenza-related pneumonia, neuraminidase inhibitors, PRIDE Consortium Investigators
Published
2015

20. Clinical characteristics and outcome of respiratory syncytial virus infection among adults hospitalized with influenza-like illness in France

Author

Loubet, P., primary, Lenzi, N., additional, Valette, M., additional, Foulongne, V., additional, Krivine, A., additional, Houhou, N., additional, Lagathu, G., additional, Rogez, S., additional, Alain, S., additional, Duval, X., additional, Galtier, F., additional, Postil, D., additional, Tattevin, P., additional, Vanhems, P., additional, Carrat, F., additional, Lina, B., additional, Launay, O., additional, Seddik, K., additional, Lesieur, Z., additional, Bonmarin, I., additional, Loulergue, P., additional, Bodilis, H., additional, Servera-Miyalou, M., additional, Sadler, I., additional, Momcilovic, S., additional, Kanaan, R., additional, Coolent, N., additional, Tan Boun, K., additional, Blanche, P., additional, Charpentier, J., additional, Daviaud, F., additional, Mongardon, N., additional, Bretagnol, A., additional, Claessens, Y.E., additional, Rozenberg, F., additional, Yazdanpanah, Y., additional, Burdet, C., additional, Harent, S., additional, Lachatre, M., additional, Rioux, C., additional, Bleibtreu, A., additional, Casalino, E., additional, Choquet, C., additional, Leleu, A., additional, Belghalem, K., additional, Colosi, L., additional, Ranaivoson, M., additional, Verry, V., additional, Pereira, L., additional, Dupeyrat, E., additional, Bernard, J., additional, Emeyrat, N., additional, Chavance, P., additional, Debit, A., additional, Aubier, M., additional, Pradere, P., additional, Justet, A., additional, Mal, H., additional, Brugiere, O., additional, Papo, T., additional, Goulenok, T., additional, Boisseau, M., additional, Jouenne, R., additional, Alexandra, J.F., additional, Raynaud-Simon, A., additional, Lilamand, M., additional, Cloppet-Fontaine, A., additional, Becheur, K., additional, Pelletier, A.L., additional, Fidouh, N., additional, Ralaimazava, P., additional, Beaumale, F., additional, Costa, Y., additional, Munier, E., additional, Betend, F., additional, Amour, S., additional, Loeffert, S., additional, Francourt, K., additional, Merle, C., additional, Letois, F., additional, Géraud, P., additional, Driss, V., additional, Noslier, S., additional, Ray, M., additional, Sebbane, M., additional, Konaté, A., additional, Bourdin, A., additional, Klouche, K., additional, Léglise, M.S., additional, Couve-Deacon, E., additional, Fruit, D., additional, Fenerol, C., additional, Vallejo, C., additional, Jouneau, S., additional, Lainé, F., additional, Thébault, E., additional, Fillatre, P., additional, Le Pape, C., additional, Beuzit, L., additional, Chau, F., additional, and Goderel, I., additional

Published
2017
Full Text
View/download PDF

21. Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data meta-analysis

Author

Muthuri, SG, Venkatesan, S, Myles, PR, Leonardi-Bee, J, Lim, WS, Al Mamun, A, Anovadiya, AP, Araujo, WN, Azziz-Baumgartner, E, Baez, C, Bantar, C, Barhoush, MM, Bassetti, M, Beovic, B, Bingisser, R, Bonmarin, I, Borja-Aburto, VH, Cao, B, Carratala, J, Cuezzo, MR, Denholm, JT, Dominguez, SR, Duarte, PAD, Dubnov-Raz, G, Echavarria, M, Fanella, S, Fraser, J, Gao, Z, Gerardin, P, Giannella, M, Gubbels, S, Herberg, J, Higuera Iglesias, AL, Hoeger, PH, Hoffmann, M, Hu, X, Islam, QT, Jimenez, MF, Kandeel, A, Keijzers, G, Khalili, H, Khandaker, G, Knight, M, Kusznierz, G, Kuzman, I, Kwan, AMC, Lahlou Amine, I, Langenegger, E, Lankarani, KB, Leo, Y-S, Linko, R, Liu, P, Madanat, F, Manabe, T, Mayo-Montero, E, McGeer, A, Memish, ZA, Metan, G, Mikic, D, Mohn, KGI, Moradi, A, Nymadawa, P, Ozbay, B, Ozkan, M, Parekh, D, Paul, M, Poeppl, W, Polack, FP, Rath, BA, Rodriguez, AH, Siqueira, MM, Skret-Magierlo, J, Talarek, E, Tang, JW, Torres, A, Torun, SH, Tran, D, Uyeki, TM, van Zwol, A, Vaudry, W, Velyvyte, D, Vidmar, T, Zarogoulidis, P, Nguyen-Van-Tam, JS, Muthuri, SG, Venkatesan, S, Myles, PR, Leonardi-Bee, J, Lim, WS, Al Mamun, A, Anovadiya, AP, Araujo, WN, Azziz-Baumgartner, E, Baez, C, Bantar, C, Barhoush, MM, Bassetti, M, Beovic, B, Bingisser, R, Bonmarin, I, Borja-Aburto, VH, Cao, B, Carratala, J, Cuezzo, MR, Denholm, JT, Dominguez, SR, Duarte, PAD, Dubnov-Raz, G, Echavarria, M, Fanella, S, Fraser, J, Gao, Z, Gerardin, P, Giannella, M, Gubbels, S, Herberg, J, Higuera Iglesias, AL, Hoeger, PH, Hoffmann, M, Hu, X, Islam, QT, Jimenez, MF, Kandeel, A, Keijzers, G, Khalili, H, Khandaker, G, Knight, M, Kusznierz, G, Kuzman, I, Kwan, AMC, Lahlou Amine, I, Langenegger, E, Lankarani, KB, Leo, Y-S, Linko, R, Liu, P, Madanat, F, Manabe, T, Mayo-Montero, E, McGeer, A, Memish, ZA, Metan, G, Mikic, D, Mohn, KGI, Moradi, A, Nymadawa, P, Ozbay, B, Ozkan, M, Parekh, D, Paul, M, Poeppl, W, Polack, FP, Rath, BA, Rodriguez, AH, Siqueira, MM, Skret-Magierlo, J, Talarek, E, Tang, JW, Torres, A, Torun, SH, Tran, D, Uyeki, TM, van Zwol, A, Vaudry, W, Velyvyte, D, Vidmar, T, Zarogoulidis, P, and Nguyen-Van-Tam, JS

Abstract

BACKGROUND: The impact of neuraminidase inhibitors (NAIs) on influenza-related pneumonia (IRP) is not established. Our objective was to investigate the association between NAI treatment and IRP incidence and outcomes in patients hospitalised with A(H1N1)pdm09 virus infection. METHODS: A worldwide meta-analysis of individual participant data from 20 634 hospitalised patients with laboratory-confirmed A(H1N1)pdm09 (n = 20 021) or clinically diagnosed (n = 613) 'pandemic influenza'. The primary outcome was radiologically confirmed IRP. Odds ratios (OR) were estimated using generalised linear mixed modelling, adjusting for NAI treatment propensity, antibiotics and corticosteroids. RESULTS: Of 20 634 included participants, 5978 (29·0%) had IRP; conversely, 3349 (16·2%) had confirmed the absence of radiographic pneumonia (the comparator). Early NAI treatment (within 2 days of symptom onset) versus no NAI was not significantly associated with IRP [adj. OR 0·83 (95% CI 0·64-1·06; P = 0·136)]. Among the 5978 patients with IRP, early NAI treatment versus none did not impact on mortality [adj. OR = 0·72 (0·44-1·17; P = 0·180)] or likelihood of requiring ventilatory support [adj. OR = 1·17 (0·71-1·92; P = 0·537)], but early treatment versus later significantly reduced mortality [adj. OR = 0·70 (0·55-0·88; P = 0·003)] and likelihood of requiring ventilatory support [adj. OR = 0·68 (0·54-0·85; P = 0·001)]. CONCLUSIONS: Early NAI treatment of patients hospitalised with A(H1N1)pdm09 virus infection versus no treatment did not reduce the likelihood of IRP. However, in patients who developed IRP, early NAI treatment versus later reduced the likelihood of mortality and needing ventilatory support.

Published
2016

22. Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data

Author

Muthuri, SG, Venkatesan, S, Myles, PR, Leonardi-Bee, J, Al Khuwaitir, TSA, Al Mamun, A, Anovadiya, AP, Azziz-Baumgartner, E, Báez, C, Bassetti, M, Beovic, B, Bertisch, B, Bonmarin, I, Booy, R, Borja-Aburto, VH, Burgmann, H, Cao, B, Carratala, J, Denholm, JT, Dominguez, SR, Duarte, PAD, Dubnov-Raz, G, Echavarria, M, Fanella, S, Gao, Z, Gérardin, P, Giannella, M, Gubbels, S, Herberg, J, Higuera Iglesias, AL, Hoger, PH, Hu, X, Islam, QT, Jiménez, MF, Kandeel, A, Keijzers, G, Khalili, H, Knight, M, Kudo, K, Kusznierz, G, Kuzman, I, Kwan, AMC, Amine, IL, Langenegger, E, Lankarani, KB, Leo, Y-S, Linko, R, Liu, P, Madanat, F, Mayo-Montero, E, McGeer, A, Memish, Z, Metan, G, Mickiene, A, Mikic, D, Mohn, KGI, Moradi, A, Nymadawa, P, Oliva, ME, Ozkan, M, Parekh, D, Paul, M, Polack, FP, Rath, BA, Rodríguez, AH, Sarrouf, EB, Seale, AC, Sertogullarindan, B, Siqueira, MM, Skret-Magierlo, J, Stephan, F, Talarek, E, Tang, JW, To, KKW, Torres, A, Törün, SH, Tran, D, Uyeki, TM, van Zwol, A, Vaudry, W, Vidmar, T, Yokota, RTC, Zarogoulidis, P, Nguyen-van-Tam, JS, Aguiar-Oliveira, ML, Al Masri, M, Amin, R, Araújo, WN, Ballester-Orcal, E, Bantar, C, Bao, J, Barhoush, MM, Basher, A, Bautista, E, Bettinger, J, Bingisser, R, Bouza, E, Bozkurt, I, Celjuska-Tošev, E, Chan, KKC, Chen, Y, Chinbayar, T, Cilloniz, C, Cox, RJ, Cuezzo, MR, Cui, W, Dashti-Khavidaki, S, du, B, El Rhaffouli, H, Escobar, H, Florek-Michalska, A, Fraser, J, Gerrard, J, Gormley, S, Götberg, S, Hoffmann, M, Honarvar, B, Hu, J, Kemen, C, Khandaker, G, Koay, KSC, Kojic, M, Kyaw, WM, Leibovici, L, Li, H, Li, X-L, Libster, R, Loh, TP, Macbeth, D, Maltezos, E, Manabe, T, Marcone, DN, Marczynska, M, Mastalir, FP, Moghadami, M, Moriconi, L, Ozbay, B, Pečavar, B, Poeppl, W, Poliquin, PG, Rahman, M, Rascon-Pacheco, A, Refaey, S, Schweiger, B, Smith, FG, Somer, A, Souza, TML, Tabarsi, P, Tripathi, CB, Velyvyte, D, Viasus, D, Yu, Q, Yuen, K-Y, Zhang, W, Zuo, W, Pediatric surgery, CCA - Innovative therapy, Muthuri, Stella G., Venkatesan, Sudhir, Myles, Puja R., Leonardi-Bee, Jo, Al Khuwaitir, Tarig S. A., Al Mamun, Adbullah, Anovadiya, Ashish P., Azziz-Baumgartner, Eduardo, Báez, Clarisa, Bassetti, Matteo, Beovic, Bojana, Bertisch, Barbara, Bonmarin, Isabelle, Booy, Robert, Borja-Aburto, Victor H., Burgmann, Heinz, Cao, Bin, Carratala, Jordi, Denholm, Justin T., Dominguez, Samuel R., Duarte, Pericles A.D., Dubnov-Raz, Gal, Echavarria, Marcela, Fanella, Sergio, Gao, Zhancheng, Gérardin, Patrick, Giannella, Maddalena, Gubbels, Sophie, Herberg, Jethro, Higuera Iglesias, Anjarath L., Hoger, Peter H., Hu, Xiaoyun, Islam, Quazi T., Jiménez, Mirela F., Kandeel, Amr, Keijzers, Gerben, Khalili, Hossein, Knight, Marian, Kudo, Koichiro, Kusznierz, Gabriela, Kuzman, Ilija, Kwan, Arthur M. C., Amine, Idriss Lahlou, Langenegger, Eduard, Lankarani, Kamran B., Leo, Yee-Sin, Linko, Rita, Liu, Pei, Madanat, Fari, Mayo-Montero, Elga, Mcgeer, Allison, Memish, Ziad, Metan, Gokhan, Mickiene, Aukse, Mikic, Dragan, Mohn, Kristin G.I., Moradi, Ahmadreza, Nymadawa, Pagbajabyn, Oliva, Maria E., Ozkan, Mehpare, Parekh, Dhruv, Paul, Mical, Polack, Fernando P., Rath, Barbara A., Rodríguez, Alejandro H., Sarrouf, Elena B., Seale, Anna C., Sertogullarindan, Bunyamin, Siqueira, Marilda M., Skret-Magierlo, Joanna, Stephan, Frank, Talarek, Ewa, Tang, Julian W., To, Kelvin K.W., Torres, Antoni, Törün, Selda H., Tran, Dat, Uyeki, Timothy M., van Zwol, Annelie, Vaudry, Wendy, Vidmar, Tjasa, Yokota, Renata T.C., Zarogoulidis, Paul, Nguyen-van-Tam, Jonathan S, Aguiar-Oliveira, Maria de Lourde, Al Masri, Malakita, Amin, Robed, Araújo, Wildo N., Ballester-Orcal, Elena, Bantar, Carlo, Bao, Jing, Barhoush, Mazen M., Basher, Ariful, Bautista, Edgar, Bettinger, Julie, Bingisser, Roland, Bouza, Emilio, Bozkurt, Ilkay, Celjuska-Tošev, Elvira, Chan, Kenny K.C., Chen, Yusheng, Chinbayar, Tserendorj, Cilloniz, Catia, Cox, Rebecca J., Cuezzo, María R., Cui, Wei, Dashti-Khavidaki, Simin, Du, Bin, El Rhaffouli, Hicham, Escobar, Hernan, Florek-Michalska, Agnieszka, Fraser, Jame, Gerrard, John, Gormley, Stuart, Götberg, Sandra, Hoffmann, Matthia, Honarvar, Behnam, Hu, Jianmin, Kemen, Christoph, Khandaker, Gulam, Koay, Evelyn S. C., Kojic, Miroslav, Kyaw, Win M., Leibovici, Leonard, Li, Hongru, Li, Xiao-Li, Libster, Romina, Loh, Tze P., Macbeth, Deborough, Maltezos, Efstratio, Manabe, Toshie, Marcone, Débora N., Marczynska, Magdalena, Mastalir, Fabiane P., Moghadami, Mohsen, Moriconi, Lilian, Ozbay, Bulent, Pečavar, Blaž, Poeppl, Wolfgang, Poliquin, Philippe G., Rahman, Mahmudur, Rascon-Pacheco, Alberto, Refaey, Samir, Schweiger, Brunhilde, Smith, Fang G., Somer, Ayper, Souza, Thiago M. L., Tabarsi, Payam, Tripathi, Chandrabhanu B., Velyvyte, Daiva, Viasus, Diego, Yu, Qin, Yuen, Kwok-Yung, Zhang, Wei, and Zuo, Wei

Subjects
Male, ANTIVIRAL TREATMENT, IMPACT, Respiratory System, CHILDREN, Neuraminidase inhibitors, Pandemic influenza, Mortality, Meta-analysis, medicine.disease_cause, THERAPY, chemistry.chemical_compound, Influenza A Virus, H1N1 Subtype, 0302 clinical medicine, Pandemic, Influenza A Virus, Influenza A virus, Zanamivir, 030212 general & internal medicine, Enzyme Inhibitors, Child, OUTCOMES, 0303 health sciences, biology, Neuraminidase inhibitor, Medicine (all), virus diseases, Middle Aged, 3. Good health, Hospitalization, Treatment Outcome, Female, Life Sciences & Biomedicine, Adolescent, Adult, Antiviral Agents, Humans, Influenza, Human, Neuraminidase, Oseltamivir, Proportional Hazards Models, Young Adult, Pandemics, Pulmonary and Respiratory Medicine, Human, medicine.drug, medicine.medical_specialty, medicine.drug_class, PANDEMIC INFLUENZA, Article, PRIDE Consortium Investigators, 03 medical and health sciences, Critical Care Medicine, General & Internal Medicine, Internal medicine, medicine, H1N1 Subtype, Intensive care medicine, Science & Technology, 030306 microbiology, business.industry, STEM-CELL TRANSPLANTATION, ADULTS, Odds ratio, Influenza, chemistry, RISK-FACTORS, biology.protein, business
Abstract

Background: Neuraminidase inhibitors were widely used during the 2009-10 influenza A H1N1 pandemic, but evidence for their effectiveness in reducing mortality is uncertain. We did a meta-analysis of individual participant data to investigate the association between use of neuraminidase inhibitors and mortality in patients admitted to hospital with pandemic influenza A H1N1pdm09 virus infection. Methods: We assembled data for patients (all ages) admitted to hospital worldwide with laboratory confirmed or clinically diagnosed pandemic influenza A H1N1pdm09 virus infection. We identified potential data contributors from an earlier systematic review of reported studies addressing the same research question. In our systematic review, eligible studies were done between March 1, 2009 (Mexico), or April 1, 2009 (rest of the world), until the WHO declaration of the end of the pandemic (Aug 10, 2010); however, we continued to receive data up to March 14, 2011, from ongoing studies. We did a meta-analysis of individual participant data to assess the association between neuraminidase inhibitor treatment and mortality (primary outcome), adjusting for both treatment propensity and potential confounders, using generalised linear mixed modelling. We assessed the association with time to treatment using time-dependent Cox regression shared frailty modelling. Findings: We included data for 29234 patients from 78 studies of patients admitted to hospital between Jan 2, 2009, and March 14, 2011. Compared with no treatment, neuraminidase inhibitor treatment (irrespective of timing) was associated with a reduction in mortality risk (adjusted odds ratio [OR] 0·81; 95% CI 0·70-0·93; p=0·0024). Compared with later treatment, early treatment (within 2 days of symptom onset) was associated with a reduction in mortality risk (adjusted OR 0·48; 95% CI 0·41-0·56; p

Published
2014

24. 2012/13 influenza vaccine effectiveness against hospitalised influenza A(H1N1)pdm09, A(H3N2) and B: estimates from a European network of hospitals

Author

Rondy, M., Launay, O., Puig-Barbera, J., Gefenaite, G., Castilla, J., De Gaetano Donati, Katleen, Galtier, F., Hak, E., Guevara, M., Costanzo, S., Moren, A., Lenzi, N., Lesieur, Z., Bonmarin, I., Duval, X., Costa, Y., Kanagaratnam, A., Yazdapanah, Y., Caseris, M., Dournon, N., Papo, T., Dossier, A., Becheur, H., Pelletier, A. -L., Mal, H., Marceau, A., Aubier, M., Bories, R., Casalino, E., Choquet, C., Houhou, N., Loulergue, P., Kanaan, R., Dumas, F., Postil, D., Alcolea, S., Rogez, S., Vanhaems, P., Regis, C., Merle, C., Foulongne, V., Ray, M., Maugueret-Doublet, V., Bourdin, A., Landreau, L., Konate, A., Corne, P., Sebbane, M., Klouche, K., Leglise, M. -S., Valette, M., Lina, B., Carrat, F., Chau, F., Diez-Domingo, J., Escribano-Lopez, B., Arnedo-Pena, A., Ruiz-Garcia, M., Tortajada-Girbes, M., Munuera, C. C., Sanudo, J. B., Larrea-Gonzalez, R., Gil-Guillen, V., Schwarz-Chavarri, G., Rahamat-Langendoen, J., Niesters, H., Ambrozaitis, A., Jancoriene, L., Mickiene, A., Kuliese, M., Velyvyte, D., Stolk, R. P., Zagminas, K., Ezpeleta, C., Chamorro, J., Artajo, P., Lameiro, F., Navascues, A., Ortega, M., Torres, M., Irure, J. J. G., Irisarri, F., Cenoz, M. G., Martinez-Baz, I., Cauda, Roberto, Donato, C., Santangelo, Rosaria, Perlasca, F., Fichera, Giovanni, Dara, M., Iacoviello, L., Olivieri, M., de Gaetano Donati K., Cauda R. (ORCID:0000-0002-1498-4229), Santangelo R. (ORCID:0000-0002-8056-218X), Fichera G., Rondy, M., Launay, O., Puig-Barbera, J., Gefenaite, G., Castilla, J., De Gaetano Donati, Katleen, Galtier, F., Hak, E., Guevara, M., Costanzo, S., Moren, A., Lenzi, N., Lesieur, Z., Bonmarin, I., Duval, X., Costa, Y., Kanagaratnam, A., Yazdapanah, Y., Caseris, M., Dournon, N., Papo, T., Dossier, A., Becheur, H., Pelletier, A. -L., Mal, H., Marceau, A., Aubier, M., Bories, R., Casalino, E., Choquet, C., Houhou, N., Loulergue, P., Kanaan, R., Dumas, F., Postil, D., Alcolea, S., Rogez, S., Vanhaems, P., Regis, C., Merle, C., Foulongne, V., Ray, M., Maugueret-Doublet, V., Bourdin, A., Landreau, L., Konate, A., Corne, P., Sebbane, M., Klouche, K., Leglise, M. -S., Valette, M., Lina, B., Carrat, F., Chau, F., Diez-Domingo, J., Escribano-Lopez, B., Arnedo-Pena, A., Ruiz-Garcia, M., Tortajada-Girbes, M., Munuera, C. C., Sanudo, J. B., Larrea-Gonzalez, R., Gil-Guillen, V., Schwarz-Chavarri, G., Rahamat-Langendoen, J., Niesters, H., Ambrozaitis, A., Jancoriene, L., Mickiene, A., Kuliese, M., Velyvyte, D., Stolk, R. P., Zagminas, K., Ezpeleta, C., Chamorro, J., Artajo, P., Lameiro, F., Navascues, A., Ortega, M., Torres, M., Irure, J. J. G., Irisarri, F., Cenoz, M. G., Martinez-Baz, I., Cauda, Roberto, Donato, C., Santangelo, Rosaria, Perlasca, F., Fichera, Giovanni, Dara, M., Iacoviello, L., Olivieri, M., de Gaetano Donati K., Cauda R. (ORCID:0000-0002-1498-4229), Santangelo R. (ORCID:0000-0002-8056-218X), and Fichera G.

Abstract

While influenza vaccines aim to decrease the incidence of severe influenza among high-risk groups, evidence of influenza vaccine effectiveness (IVE) among the influenza vaccine target population is sparse. We conducted a multicentre test-negative case–control study to estimate IVE against hospitalised laboratoryconfirmed influenza in the target population in 18 hospitals in France, Italy, Lithuania and the Navarre and Valencia regions in Spain. All hospitalised patients aged ≥18 years, belonging to the target population presenting with influenza-like illness symptom onset within seven days were swabbed. Patients positive by reverse transcription polymerase chain reaction for influenza virus were cases and those negative were controls. Using logistic regression, we calculated IVE for each influenza virus subtype and adjusted it for month of symptom onset, study site, age and chronic conditions. Of the 1,972 patients included, 116 were positive for influenza A(H1N1)pdm09, 58 for A(H3N2) and 232 for influenza B. Adjusted IVE was 21.3% (95% confidence interval (CI): -25.2 to 50.6; n=1,628), 61.8% (95% CI: 26.8 to 80.0; n=557) and 43.1% (95% CI: 21.2 to 58.9; n=1,526) against influenza A(H1N1) pdm09, A(H3N2) and B respectively. Our results suggest that the 2012/13 IVE was moderate against influenza A(H3N2) and B and low against influenza A(H1N1) pdm09.

Published
2015

25. Modélisation et aide à la décision d'intégration de nouveau vaccin dans le calendrier : exemples récents

Author

Dervaux, B., Lenne, X., Yazdanpanah, Y., Lévy-Bruhl, D., Bonmarin, I., Melliez, H., Legrand, Annette, UMR CNRS 8179, Université de Lille, Sciences et Technologies-Centre National de la Recherche Scientifique (CNRS), Département des maladies infectieuses, and Institut de Veille Sanitaire (INVS)

Subjects
[SHS.ECO]Humanities and Social Sciences/Economics and Finance, [SHS.ECO] Humanities and Social Sciences/Economics and Finance
Published
2008

27. Modélisation médico-économique de l'impact du vaccin conjugué contre le méningocoque C

Author

Dervaux, B., Strady, C., Perrocheau, A., de Wals, P., Bonmarin, I., Levy-Bruhl, D., UMR CNRS 8179, Université de Lille, Sciences et Technologies-Centre National de la Recherche Scientifique (CNRS), Département des maladies infectieuses, Institut de Veille Sanitaire (INVS), and Legrand, Annette

Subjects
[SHS.ECO] Humanities and Social Sciences/Economics and Finance, [SHS.ECO]Humanities and Social Sciences/Economics and Finance
Published
2005

31. Herpes zoster: Burden of disease in France

Author

Gonzalez Chiappe, S., primary, Sarazin, M., additional, Turbelin, C., additional, Lasserre, A., additional, Pelat, C., additional, Bonmarin, I., additional, Chosidow, O., additional, Blanchon, T., additional, and Hanslik, T., additional

Published
2010
Full Text
View/download PDF

32. Adult intensive-care patients with 2009 pandemic influenza A(H1N1) infection

Author

FUHRMAN, C., primary, BONMARIN, I., additional, BITAR, D., additional, CARDOSO, T., additional, DUPORT, N., additional, HERIDA, M., additional, ISNARD, H., additional, GUIDET, B., additional, MIMOZ, O., additional, RICHARD, J. C. M., additional, BRUN-BUISSON, C., additional, BROCHARD, L., additional, MAILLES, A., additional, PATY, A. C., additional, SAURA, C., additional, and LÉVY-BRUHL, D., additional

Published
2010
Full Text
View/download PDF

34. Oseltamivir-resistant influenza A(H1N1) viruses detected in Europe during season 2007-8 had epidemiologic and clinical characteristics similar to co-circulating susceptible A(H1N1) viruses

Author

Ciancio, B C, primary, Meerhoff, T J, additional, Kramarz, P, additional, Bonmarin, I, additional, Borgen, K, additional, Boucher, C A, additional, Buchholz, U, additional, Buda, S, additional, Dijkstra, F, additional, Dudman, S, additional, Duwe, S, additional, Hauge, S H, additional, Hungnes, O, additional, Meijer, A, additional, Mossong, J, additional, Paget, W J, additional, Phin, N, additional, van der Sande, M, additional, Schweiger, B, additional, and Nicoll, A, additional

Published
2009
Full Text
View/download PDF

46. Seasonal influenza immunisation in Europe. Overview of recommendations and vaccination coverage for three seasons: Pre-pandemic (2008/09), pandemic (2009/10) and post-pandemic (2010/11)

Author

Mereckiene, J., Cotter, S., Nicoll, A., Lopalco, P., Noori, T., Weber, J. T., D Ancona, F., Lévy-Bruhl, D., Dematte, L., Giambi, C., Valentiner-Branth, P., Stankiewicz, I., Appelgren, E., O Flanagan, D., Kral, C., Klein, J. P., Damme, P., Sabbe, M., Wuillaume, F., Kojouharova, M., Kriz, B., Kyncl, J., Hadjianastassiou, C., Soteriou, S., Krause, T. G., Emborg, H. D., Pebody, R., Kerbo, N., Filippova, I., Leino, T., Levy-Bruhl, D., Bonmarin, I., Reiter, S., Ole Wichmann, Stavrou, T., Molnar, Z., Gudnason, T., Rizzo, C., Perevoscikovs, J., Savickiene, E., Francoise, B., Melillo, T., Snijders, B., Melker, H., Smyth, B., Feiring, B., Valente, P., Fernandes, T., Popescu, R., Mcmenamin, J., Hudecova, H., Kraigher, A., Ucakar, V., Limia, A., Del Amo, I. P., Linde, A., and Cottrell, S.

47. Start of the 2014/15 influenza season in Europe: Drifted influenza A(H3N2) viruses circulate as dominant subtype

Author

Broberg, E., Snacken, R., Adlhoch, C., Beauté, J., Galinska, M., Pereyaslov, D., Brown, C., Penttinen, P., Kota, M., Simaku, A., Sarkisian, S., Torosyan, L., Popow-Kraupp, T., Rendi-Wagner, P., Schmid, D., Abdullayeva, N., Salimov, O., Gribkova, N., Shimanovich, V., Thomas, I., Hombrouck, A., Bossuyt, N., Moreels, S., Casteren, V., Ljubovic, A. D., Rodic, N. V., Korsun, N., Kojouharova, M., Georgieva, T., Drazenovic, V., Bagatzouni, D., Koliou, M., Havlickova, M., Jiřincová, H., Kyncl, J., Knudsen, L. K., Mazick, A., Ramona Trebbien, Fischer, T. K., Lilje, L., Pokras, L., Kuznetsova, N., Sadikova, O., Ikonen, N., Lyytikäinen, O., Murtopuro, S., Enouf, V., Lina, B., Valette, M., Werf, S., Bonmarin, I., Sylvie, B., Thierry, B., Turbelin, C., Belchior, E., Machablishvili, A., Zakhashvili, K., Buda, S., Schweiger, B., Kossivakis, A., Georgia, S., Mentis, A., Malisiovas, N., Csohán, Á, Rózsa, M., Jankovics, I., Molnár, Z., Löve, A., Sigmundsdóttir, G., Gudnason, T., Domegan, L., O’flanagan, D., Igoe, D., Waters, A., Duffy, M., Coughlan, S., O Donnell, J., Kaufman, Z., Mandelboim, M., Donatelli, I., Bella, A., Rizzo, C., Pompa, M. G., Puzelli, S., Castrucci, M. R., Katrenova, A., Nusupbaeva, G., Kasymbekova, K., Otorbaeva, D., Nikiforova, R., Zamjatina, N., Erne, S., Griškevicius, A., Lipnickiene, V., Mossong, J., Opp, M., Barbara, C., Melillo, T., Melillo, J. M., Zahra, G., Rakocevic, B., Vratnica, Z., Meijer, A., Teirlinck, A., Dijkstra, F., Donker, G., Rimmelzwaan, G., Lange, M. D., Hungnes, O., Bragstad, K., Hauge, S. H., Tønnessen, R., Dudman, S. G., Bednarska, K., Brydak, L. B., Zielinski, A., Guiomar, R., Pechirra, P., Cristovão, P., Costa, I., Nunes, B., Rodrigues, A., Eder, V., Spinu, C., Alexandrescu, V., Lupulescu, E., Popovici, F., Burtseva, E., Sominina, A., Dimitrijevic, D., Adrovic, S. R., Staronová, E., Mikas, J., Prosenc, K., Berginc, N., Socan, M., Casas, I., Larrauri, A., Pozo, F., Lejarazu, R. O., Pumarola, T., Brytting, M., Englund, H., Wiman, Å, Mahmud, N. N., Born, R., Cordey, S., Tishkova, F., Kamolov, M., Bosevska, G., Kuzmanovska, G., Topal, S., Korukluoglu, G., Ashirova, A., Ovliyakulova, G., Demchyshyna, I., Dykhanovska, T., Mironenko, A., Coyle, P., Maclean, A., Gunson, R., Green, H., Kearns, C., Zambon, M., Nugent, C., Moore, C., Phin, N., Pebody, R., Cottrell, S., Mcmenamin, J., Jessop, L., Dzemileva, S., Rakhimov, R., Mccauley, J., and Daniels, R.

48. 2012/13 influenza vaccine effectiveness against hospitalised influenza A(H1N1)pdm09, A(H3N2) and B: estimates from a European network of hospitals

Author

Rondy, M., Launay, O., Puig-Barberà, J., Gefenaite, G., Castilla, J., Gaetano Donati, K., Galtier, F., Hak, E., Guevara, M., Costanzo, S., Moren, A., Lenzi, N., Lesieur, Z., Bonmarin, I., Duval, X., Costa, Y., Kanagaratnam, A., Yazdapanah, Y., Caseris, M., Dournon, N., Papo, T., Dossier, A., Bécheur, H., Pelletier, A. -L, Mal, H., Marceau, A., Aubier, M., Bories, R., Casalino, E., Choquet, C., Houhou, N., Loulergue, P., Kanaan, R., Dumas, F., Postil, D., Alcoléa, S., Rogez, S., Vanhaems, P., Régis, C., Merle, C., Foulongne, V., Ray, M., Maugueret-Doublet, V., Bourdin, A., Landreau, L., Konaté, A., Corne, P., Sebbane, M., Klouche, K., Léglise, M. -S, Valette, M., Lina, B., Carrat, F., Chau, F., Díez-Domingo, J., Escribano-López, B., Arnedo-Pena, A., Ruiz-García, M., Tortajada-Girbés, M., Munuera, C. C., Sañudo, J. B., Larrea-González, R., Gil-Guillén, V., Schwarz-Chavarri, G., Rahamat-Langendoen, J., Hubert Niesters, Ambrozaitis, A., Jancoriene, L., Mickiene, A., Kuliese, M., Velyvyte, D., Stolk, R. P., Zagminas, K., Ezpeleta, C., Chamorro, J., Artajo, P., Lameiro, F., Navascués, A., Ortega, M., Torres, M., Irure, J. J. G., Irisarri, F., Cenoz, M. G., Martínez-Baz, I., Cauda, R., Donato, C., Santangelo, R., Perlasca, F., Fichera, G., Dara, M., Iacoviello, L., Olivieri, M., EpiConcept [Paris], REseau national d'Investigation clinique en VACcinologie (REIVAC), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôtel-Dieu-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de Gestion des Essais de Produits de Santé (CeNGEPS), CIC Cochin Pasteur (CIC 1417), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe hospitalier Broca-Université Paris Descartes - Paris 5 (UPD5)-Hôtel-Dieu-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), CIC Montpellier, Institut National de la Santé et de la Recherche Médicale (INSERM), Biocommunication en Cardio-Métabolique (BC2M), Université de Montpellier (UM), Centre National de Gestion des Essais de Produits de Santé (CeNGEPS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe hospitalier Broca-Hôtel-Dieu-CHU Cochin [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP]-Hôtel-Dieu-Université Paris Descartes - Paris 5 (UPD5)-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale (INSERM), Microbes in Health and Disease (MHD), Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET), and Centre National de Gestion des Essais de Produits de Santé (CeNGEPS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe hospitalier Broca-Hôtel-Dieu-Hôpital Cochin [AP-HP]

Subjects
Male, Pediatrics, Epidemiology, TEST-NEGATIVE DESIGN, medicine.disease_cause, Logistic regression, Influenza A Virus, H1N1 Subtype, 80 and over, Influenza A Virus, Influenza A virus, Medicine, PROTECTION, media_common, Aged, 80 and over, Incidence (epidemiology), Vaccination, virus diseases, Middle Aged, 3. Good health, Europe, Hospitalization, Treatment Outcome, Influenza Vaccines, H3N2 Subtype, Female, Seasons, Human, Adult, medicine.medical_specialty, Adolescent, Influenza vaccine, Settore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICA, Virus, Young Adult, Virology, Influenza, Human, Humans, media_common.cataloged_instance, H1N1 Subtype, European Union, European union, Aged, business.industry, Influenza A Virus, H3N2 Subtype, Public Health, Environmental and Occupational Health, Case-control study, Influenza, Confidence interval, Influenza B virus, Logistic Models, ANTIBODY, Case-Control Studies, CHALLENGE, business, Sentinel Surveillance, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience; While influenza vaccines aim to decrease the incidence of severe influenza among high-risk groups, evidence of influenza vaccine effectiveness (IVE) among the influenza vaccine target population is sparse. We conducted a multicentre test-negative case-control study to estimate IVE against hospitalised laboratory-confirmed influenza in the target population in 18 hospitals in France, Italy, Lithuania and the Navarre and Valencia regions in Spain. All hospitalised patients aged ≥18 years, belonging to the target population presenting with influenza-like illness symptom onset within seven days were swabbed. Patients positive by reverse transcription polymerase chain reaction for influenza virus were cases and those negative were controls. Using logistic regression, we calculated IVE for each influenza virus subtype and adjusted it for month of symptom onset, study site, age and chronic conditions. Of the 1,972 patients included, 116 were positive for influenza A(H1N1)pdm09, 58 for A(H3N2) and 232 for influenza B. Adjusted IVE was 21.3% (95% confidence interval (CI): -25.2 to 50.6; n=1,628), 61.8% (95% CI: 26.8 to 80.0; n=557) and 43.1% (95% CI: 21.2 to 58.9; n=1,526) against influenza A(H1N1) pdm09, A(H3N2) and B respectively. Our results suggest that the 2012/13 IVE was moderate against influenza A(H3N2) and B and low against influenza A(H1N1) pdm09.

50. Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection

Author

Venkatesan, Sudhir, Myles, Puja R, Bolton, Kirsty J, Muthuri, Stella G, Al Khuwaitir, Tarig, Anovadiya, Ashish P, Azziz-Baumgartner, Eduardo, Bajjou, Tahar, Bassetti, Matteo, Beovic, Bojana, Bertisch, Barbara, Bonmarin, Isabelle, Booy, Robert, Borja-Aburto, Victor H, Burgmann, Heinz, Cao, Bin, Carratala, Jordi, Chinbayar, Tserendorj, Cilloniz, Catia, Denholm, Justin T, Dominguez, Samuel R, Duarte, Pericles A D, Dubnov-Raz, Gal, Fanella, Sergio, Gao, Zhancheng, Gérardin, Patrick, Giannella, Maddalena, Gubbels, Sophie, Herberg, Jethro, Higuera Iglesias, Anjarath Lorena, Hoeger, Peter H, Hu, Xiao Yun, Islam, Quazi T, Jiménez, Mirela F, Keijzers, Gerben, Khalili, Hossein, Kusznierz, Gabriela, Kuzman, Ilija, Langenegger, Eduard, Lankarani, Kamran B, Leo, Yee-Sin, Libster, Romina P, Linko, Rita, Madanat, Faris, Maltezos, Efstratios, Mamun, Abdullah, Manabe, Toshie, Metan, Gokhan, Mickiene, Auksė, Mikić, Dragan, Mohn, Kristin G I, Oliva, Maria E, Ozkan, Mehpare, Parekh, Dhruv, Paul, Mical, Rath, Barbara A, Refaey, Samir, Rodríguez, Alejandro H, Sertogullarindan, Bunyamin, Skręt-Magierło, Joanna, Somer, Ayper, Talarek, Ewa, Tang, Julian W, To, Kelvin, Tran, Dat, Uyeki, Timothy M, Vaudry, Wendy, Vidmar, Tjasa, Zarogoulidis, Paul, Nguyen-Van-Tam, Jonathan S, PRIDE Consortium Investigators, Imperial College London, HUS Perioperative, Intensive Care and Pain Medicine, Department of Diagnostics and Therapeutics, Clinicum, Venkatesan S., Myles P.R., Bolton K.J., Muthuri S.G., Al Khuwaitir T., Anovadiya A.P., Azziz-Baumgartner E., Bajjou T., Bassetti M., Beovic B., Bertisch B., Bonmarin I., Booy R., Borja-Aburto V.H., Burgmann H., Cao B., Carratala J., Chinbayar T., Cilloniz C., Denholm J.T., Dominguez S.R., Duarte P.A.D., Dubnov-Raz G., Fanella S., Gao Z., Gerardin P., Giannella M., Gubbels S., Herberg J., Higuera Iglesias A.L., Hoeger P.H., Hu X.Y., Islam Q.T., Jimenez M.F., Keijzers G., Khalili H., Kusznierz G., Kuzman I., Langenegger E., Lankarani K.B., Leo Y.-S., Libster R.P., Linko R., Madanat F., Maltezos E., Mamun A., Manabe T., Metan G., Mickiene A., Mikic D., Mohn K.G.I., Oliva M.E., Ozkan M., Parekh D., Paul M., Rath B.A., Refaey S., Rodriguez A.H., Sertogullarindan B., Skret-Magierlo J., Somer A., Talarek E., Tang J.W., To K., Tran D., Uyeki T.M., Vaudry W., Vidmar T., Zarogoulidis P., and Nguyen-Van-Tam J.S.

Subjects
0301 basic medicine, Male, pandemic influenza, OSELTAMIVIR TREATMENT, IMPACT, Neuraminidase/antagonists & inhibitors, CHILDREN, medicine.disease_cause, 0302 clinical medicine, antivirals, Influenza A Virus, H1N1 Subtype, Adrenal Cortex Hormones, IPD meta-analysi, Influenza A virus, Immunology and Allergy, 030212 general & internal medicine, IPD meta-analysis, Young adult, Enzyme Inhibitors, Child, 11 Medical and Health Sciences, RISK, 11832 Microbiology and virology, Antiviral Agents/therapeutic use, OUTCOMES, COMPLICATIONS, biology, Neuraminidase inhibitor, Enzyme inhibitors, Middle Aged, Antivirals, antiviral, 3. Good health, Anti-Bacterial Agents, Infectious Diseases, Treatment Outcome, Meta-analysis, Cohort, Viruses, Enzyme Inhibitors/pharmacology/therapeutic use, Female, Pandemic influenza, Adult, medicine.medical_specialty, Adolescent, medicine.drug_class, 030106 microbiology, IPD meta-analysis, Neuraminidase inhibitors, antivirals, length of stay, pandemic influenza, Neuraminidase, Adrenal Cortex Hormones/therapeutic use, Microbiology, Antiviral Agents, PRIDE Consortium Investigators, Grip, 03 medical and health sciences, Major Articles and Brief Reports, Young Adult, Pharmacotherapy, Internal medicine, Influenza, Human, medicine, Humans, COHORT, Pandemics, ddc:613, Aged, Neuraminidase inhibitors, business.industry, CLINICAL-FEATURES, ADULTS, 06 Biological Sciences, Influenza, Human/drug therapy/epidemiology, Length of Stay, Confidence interval, Influenza, Editor's Choice, Anti-Bacterial Agents/therapeutic use, Inhibidors enzimàtics, 3121 General medicine, internal medicine and other clinical medicine, biology.protein, business, RESISTANCE
Abstract

Background The effect of neuraminidase inhibitor (NAI) treatment on length of stay (LoS) in patients hospitalized with influenza is unclear. Methods We conducted a one-stage individual participant data (IPD) meta-analysis exploring the association between NAI treatment and LoS in patients hospitalized with 2009 influenza A(H1N1) virus (A[H1N1]pdm09) infection. Using mixed-effects negative binomial regression and adjusting for the propensity to receive NAI, antibiotic, and corticosteroid treatment, we calculated incidence rate ratios (IRRs) and 95% confidence intervals (CIs). Patients with a LoS of, We found that neuraminidase inhibitor (NAI) treatment initiated on hospital admission to patients with clinically diagnosed or laboratory-confirmed A(H1N1)pdm09 virus infection was associated with a reduction in hospital length of stay when compared to later or no NAI treatment.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results